The Flow Cytometry Core provides USC Norris Comprehensive Cancer Center (NCCC) members access to advanced multi-parameter cellular analytic and cell sorting capabilities which includes the fluorescence activated cell sorting (FACS) of various populations of cells to provide a purified cell population for the researchers. The Core also provides expertise to allow investigators to analyze the expression of various markers on a cell population using fluorescence-based methods. This Core is administratively managed by the Broad Center for Regenerative Medicine and Stem Cell Research (CSCRM). Previously, flow cytometry services were provided by a core facility managed by NCCC with partial support from the CCSG. On December 1, 2009, NCCC partnered with CSCRM, who took over the provision of flow cytometry services to NCCC investigators under the directorship of Dr. Gregor Adams. This transition was a direct result of the NCCC Executive Committee's review of its shared resources in mid-2008, and endorsed by the NCCC's External Advisory Committee in April 2009. The partnership benefits NCCC investigators by giving them access to newer cytometers with more capabilities, as well as a reduction in the cost of flow cytometry services. The Core currently maintains four cytometers, a Beekman Coulter CyAn analyzer, a BD LSR II analyzer, BD FACSAria and BD FACSAria 11 cell sorters. The LSRII and the Aria are equipped with a 350 nm UV, a 488 nm argon laser, and a 635 nm red diode laser, while the Aria II is equipped with a 405 nm violet laser, a 488 nm argon laser and a 633 nm red diode laser, which will ultimately permit up to 15 parameter analysis.
Many cancer research projects require the isolation of a purified population of cells for analysis. The Flow Cytometry Core provides all of the necessary expertise and facilities to perform these experiments. This is an essential component of research aimed at treating many malignant conditions.
|Gopalakrishnan, R; Matta, H; Tolani, B et al. (2016) Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Oncogene 35:1797-810|
|Zeng, Chenjie; Matsuda, Koichi; Jia, Wei-Hua et al. (2016) Identification of Susceptibility Loci and Genes for Colorectal Cancer Risk. Gastroenterology 150:1633-45|
|Fanini, Francesca; Fabbri, Muller (2016) Cancer-derived exosomic microRNAs shape the immune system within the tumor microenvironment: State of the art. Semin Cell Dev Biol :|
|Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C et al. (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741-56|
|Liu, Jie; Siegmund, Kimberly D (2016) An evaluation of processing methods for HumanMethylation450 BeadChip data. BMC Genomics 17:469|
|Taylor, Nicholas J; Thomas, Nancy E; Anton-Culver, Hoda et al. (2016) Nevus count associations with pigmentary phenotype, histopathological melanoma characteristics and survival from melanoma. Int J Cancer 139:1217-22|
|Pulido, Mario A; DerHartunian, Meleeneh Kazarian; Sehgal, Prerna et al. (2016) Data on isoaspartylation of neuronal ELAVL proteins. Data Brief 9:1052-1055|
|Pannunzio, Nicholas R; Lieber, Michael R (2016) RNA Polymerase Collision versus DNA Structural Distortion: Twists and Turns Can Cause Break Failure. Mol Cell 62:327-34|
|(2016) Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res 18:64|
|Van Roosbroeck, Katrien; Fanini, Francesca; Setoyama, Tetsuro et al. (2016) Combining anti-miR-155 with chemotherapy for the treatment of lung cancers. Clin Cancer Res :|
Showing the most recent 10 out of 635 publications